Howard G C, Cornbleet M A, Whillis D, Hargreave T B, Chisholm G D
Department of Clinical Oncology, Western General Hospital, Edinburgh.
Br J Urol. 1991 Nov;68(5):490-4. doi: 10.1111/j.1464-410x.1991.tb15392.x.
A prospective study has been performed to assess the feasibility and toxicity of administering neoadjuvant chemotherapy with methotrexate (200 mg/m2) and cisplatin (100 mg/m2) prior to radical radiotherapy. Twenty patients with advanced transitional cell carcinoma of the bladder were assessed after each of 3 courses of chemotherapy, after radiotherapy and 6 months following treatment. Of particular concern was whether neoadjuvant chemotherapy compromised the ability to give potentially curative radical radiotherapy, delayed effective palliation of distressing urinary symptoms, or allowed local tumour progression prior to definitive treatment. It was concluded that this chemotherapy regimen was well tolerated, did not compromise the ability to give radical radiotherapy and resulted in the prompt palliation of urinary symptoms. This treatment, however, did not stop the development or progression of metastatic disease in some patients. In only 1 patient was there local progression during chemotherapy.
一项前瞻性研究已开展，旨在评估在根治性放疗前给予甲氨蝶呤（200 mg/m²）和顺铂（100 mg/m²）新辅助化疗的可行性和毒性。20例晚期膀胱移行细胞癌患者在3个疗程化疗的每个疗程后、放疗后及治疗后6个月接受评估。特别关注的是新辅助化疗是否会损害给予潜在根治性放疗的能力、延迟对令人痛苦的泌尿系统症状的有效缓解，或在确定性治疗前导致局部肿瘤进展。得出的结论是，这种化疗方案耐受性良好，不损害给予根治性放疗的能力，并能迅速缓解泌尿系统症状。然而，这种治疗并未阻止一些患者转移性疾病的发生或进展。化疗期间仅1例患者出现局部进展。
